Clinical Trial Update: Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting [Phase 3]

View source ↗

Summary

A Phase 3 efficacy study evaluated mupirocin for preventing surgical site infections after coronary artery bypass grafting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Surgical Site Infection

Drugs mentioned

• Mupirocin (Mupirocin)

Snippet

Sponsor: Horizon Health Network | Conditions: Surgical Site Infections | Phase 3 | Status: COMPLETED